Mirtazapine for Sleep and Appetite: When Sedation Is the Point

For most antidepressants, drowsiness and a bigger appetite are side effects to manage. With mirtazapine, they’re sometimes the reason it gets chosen, especially when depression has stolen your sleep and your appetite at the same time.

Your brain uses histamine to stay awake and a mix of serotonin and norepinephrine signals to regulate mood and hunger. Mirtazapine acts on several of these at once, and mirtazapine’s FDA label explains its prominent sleepiness through blockade of histamine H1 receptors. That receptor profile gives it unusual precision for a specific symptom cluster: poor sleep, low appetite, and low mood together.

The standard approach uses those properties deliberately. Mirtazapine is FDA-approved for major depressive disorder, and in a small randomized sleep study of people with depression and insomnia, it improved sleep latency, sleep efficiency, and nighttime waking within two weeks, while fluoxetine didn’t change those measures. The effect on sleep is real and measurable.

But a sedating effect that works in week two doesn’t automatically work in month three, and at Siggy we’d rather track that change than assume it away. Using mirtazapine well means matching it to the right symptoms, watching sleep and weight as trends, and re-checking whether the benefit is still there after the first couple of months. That approach follows the trial data on how long the effect lasts, not the reputation the drug has built.

What This Page Covers

• How Mirtazapine Causes Sleepiness and Hunger
• What the Evidence Shows for Sleep
• What the Evidence Shows for Appetite
• Is a Lower Dose Really More Sedating?
• Typical Doses and Timing
• Who Should Be Cautious
• How Siggy Supports You Over Time

How Mirtazapine Causes Sleepiness and Hunger

Mirtazapine isn’t an SSRI. The label describes it as blocking alpha-2 receptors that normally put the brakes on norepinephrine and serotonin release, and blocking several serotonin receptor types. It also blocks histamine H1 receptors, which the label links to its sleepiness, and alpha-1 receptors, which it links to dizziness on standing.

In U.S. controlled trials summarized in the label, sleepiness was reported by 54% of people on mirtazapine versus 18% on placebo, and it led 10.4% to stop treatment. Increased appetite was reported by 17% versus 2%, and 7.5% gained at least 7% of their body weight, compared with none on placebo.

If you’re struggling to sleep and struggling to eat, those numbers can read like a feature list. If you’re not, they’re the main reasons people stop taking it.

What the Evidence Shows for Sleep

The strongest sleep evidence comes from people with depression, where the two-week randomized comparison above found gains in how fast people fell asleep, how efficiently they slept, and how long they lay awake at night.

Insomnia without depression is a different question. A 2018 Cochrane review of antidepressants for insomnia found relatively few, mostly small studies and no evidence supporting long-term antidepressant use for insomnia. Mirtazapine wasn’t among the drugs it could evaluate.

A newer trial helps fill that gap. The 2025 DREAMING trial randomized 80 adults with insomnia and trouble staying asleep to low-dose mirtazapine (7.5 to 15 mg), low-dose amitriptyline, or placebo in Dutch general practices. At 6 weeks, mirtazapine lowered insomnia severity scores by 6 points more than placebo, and more than half of participants improved. From 12 weeks onward, there was no significant difference from placebo.

The authors concluded that doctors might consider off-label low-dose mirtazapine for about 6 weeks when non-drug treatment isn’t enough, but that the results don’t support prescribing it for several months.

If you do start mirtazapine for sleep, a simple log makes that 6-week check-in far more useful. Note your bedtime, wake time, how often you woke overnight, how groggy you felt the next morning, and your weight once a week. Those few numbers give you and your prescriber something concrete to review, instead of a general sense of whether it’s still working.

What the Evidence Shows for Appetite

The appetite effect is consistent in depression trials. The label notes that in a pool of premarketing studies, including many people on long-term treatment, 8% stopped mirtazapine because of weight gain.

As a stand-alone appetite drug, the picture is less clear. In a 2021 randomized trial of 120 patients with advanced cancer and appetite loss, 15 mg at night was no better than placebo at improving appetite scores after 28 days. A 2024 lung cancer trial also found no difference in appetite scores, although people on mirtazapine ate about 379 more calories a day at 4 weeks.

So mirtazapine may increase what people eat without reliably changing how hungry they feel, and results in one condition don’t automatically carry over to another.

Is a Lower Dose Really More Sedating?

You’ll often read that mirtazapine is more sedating at 7.5 or 15 mg than at 30 or 45 mg, because norepinephrine effects supposedly offset sleepiness at higher doses. It’s one of the most repeated claims about this drug, and one of the least tested.

A review by British Columbia’s academic detailing service noted that the FDA had requested a postmarketing study of dose and sedation, but its literature search found no completed trial meeting that request. An adverse event analysis of FDA reports likewise failed to support the idea that mirtazapine becomes more activating at higher doses.

The label adds one more wrinkle: it says it’s unclear whether tolerance develops to mirtazapine’s sleepiness. If a higher dose is being considered, it’s reasonable to expect that sleepiness could continue.

Typical Doses and Timing

For depression, the label recommends starting at 15 mg once daily, preferably in the evening before sleep, with increases up to 45 mg. Dose changes shouldn’t happen more often than every one to two weeks, to allow time to judge the response.

Here’s how doses line up across labeling and research.

Use	Dose	Source
Depression, starting dose	15 mg in the evening	FDA label
Depression, maximum	45 mg per day	FDA label
Depression, efficacy plateau	About 30 mg	2019 dose-response meta-analysis
Insomnia, off-label trial	7.5 to 15 mg	2025 DREAMING trial
Cancer appetite trials	15 mg, or 15 then 30 mg	2021 and 2024 randomized trials

The efficacy plateau comes from a 2019 dose-response meta-analysis in The Lancet Psychiatry, which found mirtazapine’s antidepressant effect rose up to about 30 mg and then declined, with the lower part of the licensed range offering the best balance of benefit and tolerability.

Who Should Be Cautious

Mirtazapine isn’t the right fit for everyone, and a few groups need a closer look before starting:

• People with a personal or family history of bipolar disorder, since the label calls for screening before any antidepressant.
• People for whom weight gain would be a serious health problem.
• Anyone who drives early in the morning or works in safety-sensitive jobs, because the label warns sleepiness may impair judgment and motor skills.
• People with liver disease or significant heart disease, who need extra monitoring.

The label also warns about rare but serious reactions, including a severe drop in white blood cells. Report fever, sore throat, or mouth sores right away. Like all antidepressants, mirtazapine carries a boxed warning about suicidal thoughts in young people. If you ever have thoughts of harming yourself, call 911 or go to the nearest emergency room.

How Siggy Supports You Over Time

“Suffering with insomnia and depressive thoughts for months makes life miserable.” When sleep and mood fall apart together, a medication that helps with both can feel like a lifeline, and it’s easy to keep taking it long after anyone has checked whether it’s still doing its job.

Siggy is built around that follow-through. You start with a free, anonymous intake, with no name, email, or login, and a licensed prescriber reviews your treatment plan before anything is prescribed. Siggy’s current care focuses on SSRI-based treatment for anxiety and depression, and it’s designed to follow how your sleep, appetite, and mood change over time, so your prescriber sees the trend instead of guessing at it.

Mirtazapine earns its place when sedation and appetite are the goal, but the evidence says its sleep benefit can fade and its appetite effect isn’t universal. That makes it a medication worth re-checking, not one to set and forget. If you’re comparing sedating options for sleep, our plain-English guide to low-dose trazodone for sleep covers the other antidepressant most often used this way.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Talk with your own clinician before starting, changing, or stopping any medication.